Hormone resistance in prostate cancer

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 373-381

  Pilat, Mary Josephine P ^a   Kamradt, Jeffery M ^a   Pienta, Kenneth J ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Androgen receptor; Androgen independent; Hormone refractory; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PREDNISONE; STRONTIUM 89; VINBLASTINE;

CELL PROLIFERATION; DIMERIZATION; ERYTHEMA; GENE EXPRESSION; HORMONE RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; STOMATITIS; TERMINAL CARE;

EID: 0032807905     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006166511344     Document Type: Review

References (71)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics, 1999. CA Cancer J Clin 49: 6-29, 1999
2. Isaacs JT, Coffey DS: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3227-H adenocarcinoma. Cancer Res 41: 5070-75, 1981
3. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM: Metastatic prostate cancer in a transgenic mouse. Cancer Res 56: 4096-102, 1996
4. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM: Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57: 4687-91, 1997
5. Kovisto P, Kolmer M, Visakorpi T, Kallioniemi OP: Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152: 1-9, 1998
6. Barrack ER: Androgen receptor mutations in prostate cancer. Mount Sinai J Med 63: 403-12, 1996
7. Tilley WD, Buchanan G, Hickey TE, Bentley JM: Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2: 277-85, 1996
8. Dorkin TJ, Robson CN, Neal DE: The molecular pathology of urological malignancies. J Pathology 183: 380-87, 1997
9. Quarmby VE, Beckman WC Jr, Cooke DB, Lubahn DB, Joseph DR, Wilson EM: Expression and localisation of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res 50: 735-39, 1990
10. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ: Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 50: 5382-86, 1990
11. Bentel JM, Tilley WD: Androgen receptors in prostate cancer. J Endocrinol 151: 1-11, 1996
12. Van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroohoven CC, Mulder G, Roersman W, Trapman J: Androgen receptors in endocrine therapy-resistant human prostate cancer. Int J Cancer 48: 189-93, 1991
13. Visakorpi T, Hyytinen E, Kovisto P, Tanner M, Keinanen R, Palmher C, Palotie A, Tammela T, Isola J, Kallioniemi OP: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 9: 401-6, 1995
14. Labrie F, DuPont A, Balanger A, St-Amaud R, Giguere M, Lacourciere Y, Emond J, Monfette G: Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrine Rev 7: 67-74, 1986
15. Crawford ED, DeAntoni EP, Hussain M, Thompson IM, Coltman CA: Prostate cancer clinical trials of the southwest oncology group. Oncology 11; 1154-63, 1997
16. Blok LJ, Kumar V, Tindall DJ: Isolation of cDNAs that are differentially expressed between androgen-dependent and androgen-independent prostate adenocarcinoma cells using differential display PCR. Prostate 26: 213-24, 1995
17. Chang GT, Blok LJ, Steenbeek M, Veldscholte J, van Weerden WM, van Steenbrugge GJ, Brinkmann AO: Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res 57: 4075-81, 1997
18. Schwab ED, Choeypunt N, Pienta KJ: Identification of genes involved in prostate cancer metastasis by mRNA differential display. Proc Amer Assoc Cancer Res 37: 86, 1997
19. Schwab ED, Pienta KJ: Identification of two genes associated with metastatic prostate cancer. Proceedings of the Am Urolog Ass 93rd meeting: 1, Abstract #2, 1998
20. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM: Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Med 4: 50-7, 1998
21. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M: Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 63: 1714-20, 1989
22. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW: Endothelin-1 prodution and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56: 663-68, 1996
23. Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M, Maihle NJ: Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci USA 91: 4673-77, 1994
24. Dorkin TJ, Robson CN, Neal DE: The molecular pathology of urological malignancies. J Pathology 183: 380-87, 1997
25. Figueroa JA, DeRaad S, Tadlock L, Speights VO, Rinehart JJ: Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J of Urol 159: 1379-83, 1998
26. Fong C-J, Sherwood ER, Mendelsohn J, Lee C, Kozlowski J: Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor-α. Cancer Res 52: 5887-92, 1992
27. Hofer DR, Sherwood E, Bromberg WD, Mendelsohn J, Le C, Kozlowski J: Autonomous growth of androgen-independent prostatic carcinoma cells: role of transforming growth factor a. Cancer Res 51: 2780-85, 1991
28. Pietrzkowski Z, Mulholland G, Gomelia L, Jameson BA, Wernicke D, Baserga R: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor. Cancer Res 53: 1102-06, 1993
29. Rajah R, Valenitinis B, Cohen P: Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272: 12181-8, 1997
30. Nazareth LV, WeigEl NL: Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271: 19900-907, 1996
31. Yeh S, Chang C: Cloning and characterization of a specific coactivator, ARA 70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93: 5517-21, 1996
32. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinol 122: 552-62, 1988
33. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993
34. Aihara M, Scardino PT, Truong LD, Wheeler TM, Goad JR, Yang G, Thompson TC: The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer 75: 522-29, 1995
35. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML: Expression of the protooneogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-44, 1992
36. Shi XB, Gumerlock PH, de Vere Whit RW: Molecular biology of prostate cancer. World J Urol 14: 318-28, 1996
37. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53: 3369-73, 1993
38. Kantoff PW. New agents in the therapy of hormone-refractory prostate cancer. Semin Oncol 22: 32-34, 1995
39. Millikan R, Logothetis C: Update of the NCCN guidelines for treatment of prostate cancer. Oncology 11: 180-93, 1997
40. Esper PS, Pienta KJ: Supportive care in the patient with hormone refractory prostate cancer. Semin Urol Oncol 15: 56-64, 1997
41. Hamdy FC, Williams JL: Use of dexamethasone for ureteric obstruction in advanced prostate cancer: percutaneous nephrostomies can be avoided. Br J Urol 75: 782-85, 1995
42. Tannock I, Gospodarowicz Meakin W, Panzarella T, Stewart L, Rider W: Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7: 590-97, 1989
43. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL: Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76: 96-100, 1995
44. Adami S: Bisphosphonates in prostate cancer. Cancer 80: 1674-79, 1997
45. Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ: Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12: 683-88, 1994
46. Dexeus F, Logothetis CJ, Samuels ML, Hossan E, Von Escherbach AC: Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 69: 885-86, 1985
47. Batra S, Karlsson R, Witt L: Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells. Int J Cancer 68: 644-49, 1996
48. Hudes GR, Greenberg R, Kriegel RL, Fox S, Scher R, Litwin S, Watts P, Speicher L, Tew K, Comis R: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10: 1754-61, 1992
49. Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T: Estramustine and vinblastine: use of prostate specific antigen as a clinical trial endpoint for hormone refractory prostatic cancer. J Urol 147: 931-34, 1992
50. Attivissimo LA, Fetten JV, Kreis W: Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Am J Clin Oncol 19: 581-83, 1996
51. Pienta KJ, Lehr JE: Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 149: 1622-25, 1993
52. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12: 2005-12, 1994
53. Pienta KJ, Redman BG, Bandekar R, Strawderman MA, Cease K, Esper PS, Naik H, Smith DC: Phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50: 401-07, 1997
54. Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, Constantinidis C, Kostakopoulos A, Kastriotis I, Zervas A, Aravantinos G, Dimopoulos C: Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 50: 754-58, 1997
55. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loerher PJ: Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 72: 2457-60, 1993
56. Pienta KJ, Naik H, Lehr JE: Effect of estramustine, etoposide and taxol on prostate cancer cell growth in vitro and in vivo. Urology 48: 164-70, 1996
57. Speicher LA, Barone L, Tew KD: Combined antimicrotubule activity of estramustine and taxol in human prostalic carcinoma cell lines. Cancer Res 52: 4433-40, 1992
58. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAlecr C: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15: 3156-63, 1997
59. Smith DC, Esper PS, Todd III RT, Pienta KJ: Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Proc Annu Meet Am Soc Clin Oncol 16: 1105 (Abstract), 1997
60. Kamradt JM, Smith DC, Pienta KJ: Hormone-refractory prostate cancer: national comprehensive cancer network guidelines. Adv Onc 14: 14-21, 1998
61. Osborne CK, Drelichman A, Von Hoff DD, Crawford ED: Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep 67: 1133-35, 1983
62. Kantoff PW, Block C, Letvak L, George M: 14-day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate. Am J Clin Oncol 16: 489-91, 1993
63. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J: Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12: 689-94, 1994
64. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CML, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints. J Clin Oncol 14: 1756-64, 1996
65. Kozlowski JM, Ellis WJ, Grayhack JT: Advanced prostatic carcinoma - early versus late endocrine therapy. Urol Clin North Am 18: 15-24, 1991
66. Silberstein EB: The treatment of painful osseous metastases with phosphorous-32 labeled phosphates. Semin Oncol (20 No 3 Suppl 2): 10-21, 1993
67. Robinson RG, Blake GM, Preston DF, McEwan AJ, Spicer JA Martin NL, Wegst AV, Ackery DM: Strontium-89 treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 9: 271-81, 1989
68. McEwan AJB, Porter AT, Venner PM, Amyotte G: An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy. Antibody Immunoconjugates Radiopharm 3: 91-96, 1990
69. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA: A prospective randomised double-blind crossover study to determine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 27: 954-58, 1991
70. Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJ, Macleod PM, Zivanovic MA: Strontium-89 for pain palliation in prostatic skeletal malignancy. Br J Radiol 64: 816-22, 1991
71. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, Sathyunarayana JR, Yakemchuk VN, Thomas GM, Erlich LE: Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local filed external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25: 805-13, 1993